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Background: This retrospective study was designed to investigate the clinical characteristics, diagnosis, treatment
and prognosis of primary tracheobronchial mucoepidermoid carcinoma (MEC).
Methods: Clinical data were retrospectively analyzed from 32 patients with pathologically confirmed primary
tracheobronchial MEC between January 1990 and December 2010 at Zhejiang Cancer Hospital. The Kaplan-Meier
methods were used to estimate and compare survival rates.
Results: There were 19 males and 13 females ranging in age from 7 to 73 years, with a median age of 28 years.
Twenty-six of the 32 patients were treated with surgery alone. The other six patients were treated with surgery plus
postoperative radiotherapy or chemotherapy. Six patients died during the follow-up time. The overall five-year
survival rates were 81.25%, whereas the five-year survival rate of seven patients with high-grade tumors was only
28.6%. Stage I and II patients experienced better survival than Stage III and IV patients (the five-year survival rate
was 100% and 43.6% respectively, P<0.001).
Conclusions: Primary tracheobronchial MEC is a rare disease. Histologic grading and TNM (tumor-node-metastasis)
staging are independent prognostic factors. Surgical resection is the primary treatment.
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Primary mucoepidermoid carcinoma (MEC) of the tra-
cheobronchial is an uncommon neoplasm, constituting
only 0.1% to 0.2% of primary lung malignancies [1]. Its
biological behavior and prognosis have not been well
studied. Surgical resection is still the primary treatment
[2,3]. This report reviews the clinical characteristics, diag-
nosis, treatment and prognosis of 32 cases with primary
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reproduction in any medium, provided the orin this study. The Ethics Committee at Zhejiang Cancer
Hospital approved the study. All patients were reviewed
concerning their medical history and underwent physical
examinations. The staging was performed for all patients
according to the seventh TNM (tumor-node-metastasis)
classification [4] in bronchial MEC. Bhattacharyya’s [5]
staging system was adopted and used in tracheal MEC.
The pathology was according to the World Health
Organization Classification of Tumors (2004). Patient
selection criteria are: (1) pathologically proven primary
tracheobronchial mucoepidermoidcarcinoma; (2) all the
patients were confirmed using chest computed tomog-
raphy (CT), brain magnetic resonance imaging (MRI)
and bone scan as well as ultrasound, and/or CT of the
abdomen before surgery.Statistical analysis
The survival time was calculated from the start of treat-
ment to the point of death or the last follow-up. The sur-
vival curves were calculated based on the method of
Kaplan-Meier. Values of P<0.05 were considered significant.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical characteristics of 32 patients
Gender
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SPSS version 16.0 (SPSS Inc., Chicago, IL, USA).Male 19
Female 13
Age






After surgical intervention, patients were examined in
the outpatient clinic at three-month intervals for the
first two years and, thereafter, at six-month intervals.
During follow-up periods, contrast enhanced CT scans
of the chest were routinely performed at the same inter-
vals as visits to the outpatient clinic. Follow-up data
were obtained by retrospective review of the patient’s













Over the past 20 years, 8,310 patients were diagnosed
with respiratory tumors in our hospital, and 32 of them
were tracheobronchial primary MEC, which accounted
for 0.38% of the whole population. This study group
comprised 19 males and 13 females ranging in age from
7 to 73 years (median age, 28 years). According to the
TNM staging system and Bhattacharyya’s staging system,
the study included 10 Stage I, 8 Stage II, 11 Stage III,
and 3 Stage IV patients (all 3of these patients were tra-












All 32 patients underwent surgery, including 28 cases of
radical excision and 4 cases of palliative resection. Thir-
teen tumors were located in tracheal and 19 in bronchial
areas. Postoperative complications included one case of
pneumonia. No patients died during treatment in the
hospital. Twenty-seven patients who underwent oper-
ation were treated with surgery alone. There were 9
parenchyma-saving procedures (4 sleeve lobectomies, 1
upper and middle sleeve lobectomy, 2 main bronchus
sleeve resection with end-to-end anastomosis, 2 main
bronchus sleeve resection), 10 resection of anatomically
related lung parenchyma (3 bilateral lobectomies, 6 lob-
ectomies, 1 pneumonectomy) and 13 local tumor resec-
tions including 3 tumor resections plus carinaplasty, 4
single local tumor resection and 6 tracheal resection and
end to end anastomosis. Among 32 patients, 11 were
assigned to receive mediastinal lymphadenectomy, 21
without lymphadenectomy. Six patients were treated
with surgery plus postoperative radiotherapy or chemo-
therapy. Chemotherapy was administered following re-
section in five of the seven high-grade MEC patients.
The regimen comprisedNP (vinorelbine + cisplatin) regi-
men in four patients and DP (decetaxol + cisplatin) in
one patient. One patient received postoperative radio-
therapy for the positive resection margin.Follow-up and prognosis
Mean follow-up duration was 102 months (range 12 to
196). No patients were lost to follow-up. Six patients died
during the follow-up. Five with high-grade histology and
one with low-grade (Figure 1A, B). The overall five-year
survival rates were 81.25%, whereas the five-year survival
of seven patients with high-grade tumors was only 28.6%
(Figure 2). The overall five-year survival rates were 100%
compared with 43.6% between the Stage (I + II) and Stage
(III + IV) patients, P<0.001) (Figure 3).
Figure 1 (A) Tracheobronchial MEC with a high grade
pathological diagnosis (HE; original magnification × 40).
(B) Tracheobronchial MEC with a low grade pathological diagnosis
(HE; original magnification × 40).
Figure 2 Kaplan-Meier curves comparing survival of patients
with different histological grades.
Figure 3 Kaplan-Meier curves comparing survival of patients
with early TNM stage and late stage tumors.
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Primary tracheobronchial MEC is relatively uncommon,
accounting for less than 1% of all cases of primary tra-
cheobronchial carcinoma. The tumor was first described
by Smetana et al.and Liebowet al. in 1952 [6,7]. Tra-
cheobronchial MEC accounted for 0.38% of all pulmon-
ary carcinomas at our institution. The frequency is
similar to the previous reports.
Primary tracheobronchial MEC affects people of all
ages and more than half of the patients were younger
than 30 years [8-10]. In our series, 16 of the 32 patients
were younger than 30 years, with a median age of 28
years in all of our patients (range of 7 to 73 years). A
male predominance was described by many studies
[11,12]. Nineteen cases were male and 13 were female in
our series. The association with cigarette smoking was
not notable [13,14], with only 5 of 32 patients in our
study being current or ever smokers.MEC of the trachea and bronchi are classified as low-
grade or high-grade based on nuclear pleomorphism,
mitotic activity and the presence or absence of necrosis
[15]. The clinical behavior of tracheobronchial MEC has
been reported to vary from low malignancy to highly
malignant. Patients with low grade histology tend to be-
have in a low malignancy and do not require chemother-
apy or radiotherapy with complete resection [14,15]. The
present study also found significantly better survival in
patients with histologically low-grade tumors than in pa-
tients with high-grade tumors.
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of prognosis in patients with tracheobronchial MEC
[2,16]. The five-year survival rates were 100% in Stage I
and Stage II patients in our series; however, all of the six
patients who died were Stage III and Stage IV patients.
Standard treatment for MEC is surgical resection [17].
Common surgical procedures include lobectomy, sleeve
resection, local resection, segmental resection or endo-
scopic removal. It is difficult to remove tumors with an
adequate margin in some cases, especially T4 tumors that
are too large and are localized near important organs, so
neo-chemotherapy may be an effective treatment.
Postoperative chemotherapy is not suggested for pa-
tients with low-grade MEC. Adjuvant chemotherapy or
radiotherapy can be considered for patients with incom-
plete resection or advanced disease, but there is no
strong evidence about their roles. In the present study,
chemotherapy was administered following resection in
five of the seven high-grade MEC patients; however, all
of the patients had recurrence and four of them died
during the follow-up.
Conclusion
In summary, primary MEC of the tracheobronchial is a rare
disease. Histological grade and TNM staging appear to be
independent prognostic factors in our data. Surgical resec-
tion is the primary treatment. It is necessary to achieve fur-
ther improvements in the clinical outcome of patients with
such tumors by developing new therapeutic modalities.
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